Recently, the toolbox for treating COVID-19 and preventing severe disease has been expanded with several new treatment therapies. So far, the European Medicines Agency (EMA) has approved six COVID-19 treatments and four additional drugs are currently under review. The COVID-19 treatments authorized for use in the European Union are:
Kineret: For treatment of COVID-19 in adults with pneumonia requiring supplemental oxygen and who are at risk of developing severe respiratory failure.
Regkirona: For treatment of adults with COVID-19 who do not require supplemental oxygen and who are at risk of developing severe disease.
RoActemra: For treatment of adults with COVID-19 who are receiving corticosteroids and require extra oxygen or mechanical ventilation.
Ronapreve: For treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at risk of developing severe disease.
Vecklury: For treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen. Can also be used in adults who do not require supplemental oxygen and who are at risk of developing severe COVID-19.
Xevudy: For treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at risk of developing severe disease.
Read more at Läkemedelsverket (Swedish) or the European Medicines Agency (English)
Are you involved in the clinical development of a new, cutting-edge therapy? Contact us to discuss how we can support you in your journey towards improving patient health.
